X

Trial Profile

A Phase 1, Absorption, Metabolism, and Excretion Study of [14C]AR882 Orally Administered to Healthy Adult Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AR 882 (Primary)
Indications Gout; Hyperuricaemia
Focus Pharmacokinetics
Sponsors Arthrosi Therapeutics

Most Recent Events

02 Nov 2021 According to an Arthrosi Therapeutics media release, results from this trial will be shared at the 2021 American College of Rheumatology Convergence.
02 Nov 2021 Results published in an Arthrosi Therapeutics Media Release.
14 Aug 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com